Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy

BJU International

Volumn 106, Issue 2, 2010, Pages 218-223

  Kutikov, Alexander ^a   Uzzo, Robert G ^a   Caraway, Aaron ^b   Reese, Carl T ^b   Egleston, Brian L ^a   Chen, David Y T ^a   Viterbo, Rosalia ^a   Greenberg, Richard E ^a   Wong, Yu Ning ^a   Raman, Jay D ^b   Boorjian, Stephen A ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

metastases; nephrectomy; renal cell carcinoma; systemic therapy; targeted therapy

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; IMMUNOTHERAPY; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEPHRECTOMY; PERIOPERATIVE COMPLICATION; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; REFUSAL TO PARTICIPATE; SYSTEMIC THERAPY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77953821449     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.09079.x     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008 58 : 71 96
2. Pantuck AJ, Zisman A, Belldegrun A. Biology of renal cell carcinoma: changing concepts in classification and staging. Semin Urol Oncol 2001 19 : 72 9
3. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999 17 : 2530 2540
4. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007 356 : 115 124
5. Belldegrun AS, Klatte T, Shuch B et al. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies. Cancer 2008 113 : 2457 2463
6. Montie JE, Stewart BH, Straffon RA, Banowsky LH, Hewitt CB, Montague DK. The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J Urol 1977 117 : 272 275
7. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Poppel HV, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004 171 : 1071 1076
8. Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001 345 : 1655 1659
9. Mickisch GHJ, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001 358 : 966 970
10. Zini L, Capitanio U, Perrotte P et al. Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma. Urology 2009 73 : 342 346
11. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007 356 : 125 134
12. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007 356 : 2271 2281 (Pubitemid 46849157)
13. Rini BI, Campbell SC. The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy. J Urol 2007 177 : 1978 1984
14. Green FL. American Joint Committee on Cancer. American Cancer Society: AJCC Cancer Staging Manual, 6th edn.
15. Eble J. World Health Organization. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs.
16. Rendon RA. New surgical horizons: the role of cytoreductive nephrectomy for metastatic kidney cancer. Can Urol Assoc J 2007 1 : S62 8
17. Walther MM, Yang JC, Pass HI, Linehan WM, Rosenberg SA. Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J Urol 1997 158 : 1675 1678
18. Kassouf W, Sanchez-Ortiz R, Tamboli P. et al. Cytoreductive nephrectomy for T4NxM1 renal cell carcinoma: The M.D. Anderson Cancer Center experience. Urology 2007 69 : 835 838 (Pubitemid 46670221)
19. Matin SF, Madsen LT, Wood CG. Laparoscopic cytoreductive nephrectomy: The M.D. Anderson Cancer Center experience. Urology 2006 68 : 528 532
20. Yabroff KR, Harlan L, Stevens J, Martin A. Patterns of care in adults with renal cell carcinoma: findings in a population based sample. J Urol 2009 181 : 2462 2468
21. Shuch B, La Rochelle JC, Wu J et al. Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance. Cancer 2008 113 : 1324 1331
22. Bennett RT, Lerner SE, Taub HC, Dutcher JP, Fleischmann J. Cytoreductive surgery for stage IV renal cell carcinoma. J Urol 1995 154 : 32 4
23. Margulis V, Matin SF, Wood CG. Cytoreductive nephrectomy in metastatic renal cell carcinoma. Curr Opin Urol 2008 18 : 474 480
24. Lara PN, Tangen CM, Conlon SJ, Flanigan RC, Crawford ED. Predictors of survival of advanced renal cell carcinoma. Long-term results from the Southwest Oncology Group Trial S8949. J Urol 2009 181 : 512 517
25. Thomas AA, Rini B, Lane BR et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol 2009 181 : 518 523
26. Margulis V, Wood CG. Cytoreductive nephrectomy in the era of targeted molecular agents: is it time to consider presurgical systemic therapy? Eur Urol 2008 54 : 489 492
27. Margulis V, Matin SF, Tannir N et al. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol 2008 180 : 94 8
28. Shuch B, Riggs SB, LaRochelle JC et al. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int 2008 102 : 692 696
29. Leibovich BC, Han KR, Bui MH et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003 98 : 2566 2575
30. Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS. Resection of metastatic renal cell carcinoma. J Clin Oncol 1998 16 : 2261 2266 (Pubitemid 28265066)